Taipei-based mobile health platform iXensor has launched a new telehealth service to support fertility monitoring at home.

WHAT IT'S ABOUT

The Eveline·Care telehealth service enables fertility consultants to access patient's ovulation test data and recorded symptoms via a dashboard, which also presents their hormone profile chart. 

Users of the Eveline app must first authorise fertility consultants to access their data, including their luteinising hormone (LH) levels, basal body temperature, mood, diet and daily symptoms. Physicians are able to remotely monitor a patient's fertility condition in real-time and provide consultation through the Eveline·Care platform. 

The telehealth service is based on Eveline, iXensor's AI-powered ovulation prediction kit, which turns smartphones into at-home testing tools. A smart scanner empowers a smartphone camera to analyse LH test strips and inform the user's current ovulation status with 99% accuracy. Aside from delivering personalised notifications, the Eveline app can also predict up to five fertile days per menstruation cycle. 

WHY IT MATTERS

According to a press statement, the latest telehealth service can help patients better understand their hormonal patterns and facilitate easier communication with doctors. 

iXensor emphasises that its telehealth service supports intrauterine insemination (IUI) treatments. Once an LH surge is detected, the Eveline·Care platform automatically notifies a physician who can then invite their patient to the clinic in time for the IUI procedure. "This solution increases the chance of a successful IUI treatment by reducing the risk scenario that the patient ovulates earlier than expected," the company explained.

MARKET SNAPSHOT

Last year in January, a telemedicine platform called CurieMD was introduced in California, offering women remote consultations and mail-order prescriptions of menopause hormone replacement therapies.

In July this year, London-based Bia Care opened its virtual clinic that offers hormone replacement therapy, nutrition advice, physiotherapy and emotional fitness. 

In the same month, Inito, a medical device maker based in the US, unveiled its at-home fertility test, months after receiving US FDA approval. The ovulation test measures estrogen and LH levels to predict fertile days, as well as progesterone to confirm if ovulation has actually occurred. The device can be paired with a smartphone app to provide users with personalised results.